ABOS - Acumen Pharma at 11-month high on rivals' Alzheimer's data

• The shares of microcap biotech Acumen Pharmaceuticals, Inc. ( NASDAQ: ABOS ) more than doubled in value on Wednesday after its rivals Biogen ( BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESALY ) announced promising late-stage data for experimental Alzheimer's therapy, lecanemab.
• In the trial involving nearly 1,800 patients, the amyloid targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer's by 27%, compared to placebo, the companies announced late Tuesday.
• With data validating the amyloid hypothesis in Alzheimer's, the companies with similar drugs in development surged in value.
• Acumen ( ABOS ) is advancing its only drug candidate, ACU193 for Alzheimer's, with topline data from a Phase 1 trial expected in H1 2023.
• ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, which, according to the company, are the most toxic and pathogenic form of amyloid-beta.

For further details see: